Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee

William Nassib William, Daniel Brungs, Emerson Fernandes de Sousa e Castro, Herbert H. Loong, James C. H, Kyung-Ah Park, Mehmet ali Nahit Sendur, Mohsen Mokhtar, Se-Hoon Lee, Senthil Rajappa, Stephanie P. L, Tsung-Ying Yang, Tuncay Göksel

Therapeutic Advances in Medical Oncology

Published online on August 04, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate currently under investigation in clinical trials of various solid tumors. In this manuscript, an international steering committee formed by medical oncologists, ophthalmologists, and ...